India finds Nestle baby food sample substandard, takes legal action, bringing infant nutrition and marketing practices under renewed regulatory scrutiny. The Food Safety and Standards Authority of India (FSSAI) has initiated three separate adjudication cases against Nestle India involving three infant nutrition products. The action combines a laboratory finding concerning biotin with concerns over promotional claims made for two other products.
FSSAI Tightens Oversight of Infant Nutrition
The latest action comes amid heightened regulatory attention to food quality, labelling and promotional claims. Infant nutrition is particularly sensitive because products are consumed during an important stage of child development and are subject to specific Indian regulations governing composition, labelling and promotion.
FSSAI examined products and promotional material available through e-commerce platforms before initiating proceedings against Nestle India. The regulator's action reflects a broader emphasis on verifying not only what food products contain, but also how their nutritional attributes are presented to consumers.
Biotin Finding Triggers Separate Legal Case
The most significant technical issue concerns a Nestle follow-up formula. FSSAI said laboratory analysis found the sample to be substandard with respect to biotin, or vitamin B7, an essential nutrient. The sample was subsequently sent for re-analysis, and the referral laboratory also found it non-conforming with the prescribed biotin requirement under India's infant-nutrition regulations.
The finding does not by itself establish that every unit of the product was deficient, and the regulatory proceedings will determine the consequences. FSSAI has nevertheless treated the laboratory result as sufficient to initiate adjudication proceedings.
Promotional Claims Face Regulatory Questions
Two other cases concern NAN Excella Pro Stage 1 and Lactogen Pro 1. FSSAI has challenged promotional material associated with claims including “5 HMOs” and whey protein for NAN Excella Pro Stage 1, while Lactogen Pro 1 faces scrutiny over a claim describing its whey protein as “easy to digest.”
According to the regulator, such promotional material contravenes provisions of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, alongside restrictions under the Infant Milk Substitutes Act, 1992. The rules impose stringent controls on advertising and promotional practices involving infant foods.
Nestle Defends Compliance Position
Nestle India has rejected the suggestion that its products are non-compliant. The company said its products comply with applicable regulations and noted that the labels under scrutiny had been approved by an FSSAI expert committee. It also said the claims were factual and supported by scientific literature, while confirming that it would continue cooperating with the regulator.
The proceedings will now determine the regulatory consequences, rather than the allegations themselves constituting a final finding of liability.
Nestle’s Earlier Regulatory Controversies
The latest action also comes against the backdrop of earlier regulatory controversies involving Nestle India. The most prominent was the 2015 Maggi noodles episode, when food-safety authorities ordered a nationwide recall after tests found lead levels above permissible limits and raised concerns over labelling. The company challenged the action and Maggi eventually returned to the market after subsequent testing. More recently, Nestle’s Maggi soups and related products have also faced scrutiny over labelling and nutritional claims. While these episodes involved different products and regulatory issues, they have kept Nestle’s compliance and quality-control practices under sustained public attention.
Baby Food Regulation Faces a Critical Test
The three cases place quality control, scientific substantiation and responsible marketing at the centre of India's infant-nutrition debate. For consumers, the episode reinforces the importance of reliable product information and regulatory oversight. For Nestle, it creates a significant compliance challenge in a strategically important market. Most importantly, the adjudication process will establish whether the concerns identified by FSSAI warrant penalties or further corrective action, while setting an important precedent for how infant food is manufactured, labelled and marketed in India.
(With agency inputs)
